NR1H4 and metabolic dysfunction-associated steatotic liver disease: Clinical trial data supports the effectiveness of obeticholic acid, an FXR agonist, in inhibiting hepatic glucose and lipid metabolism, as well as exhibiting anti-inflammatory and anti-fibrotic properties in NAFLD (95).